588 related articles for article (PubMed ID: 26740249)
61. Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment.
Darrudi A; Daroudi R; Yunesian M; Akbari Sari A
Pharmacoecon Open; 2022 Sep; 6(5):669-679. PubMed ID: 35997900
[TBL] [Abstract][Full Text] [Related]
62. Adolescent girls' preferences for HPV vaccines: a discrete choice experiment.
Brown DS; Poulos C; Johnson FR; Chamiec-Case L; Messonnier ML
Adv Health Econ Health Serv Res; 2014; 24():93-121. PubMed ID: 25244906
[TBL] [Abstract][Full Text] [Related]
63. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
Medini D; Stella M; Wassil J
Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
[TBL] [Abstract][Full Text] [Related]
64. Individual preferences for COVID-19 vaccination in China.
Leng A; Maitland E; Wang S; Nicholas S; Liu R; Wang J
Vaccine; 2021 Jan; 39(2):247-254. PubMed ID: 33328140
[TBL] [Abstract][Full Text] [Related]
65. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.
Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R
Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756
[TBL] [Abstract][Full Text] [Related]
66. Sociodemographic determinants of vaccination and willingness to pay for COVID-19 vaccines in Hungary, results of a cross-sectional online questionnaire.
Beretzky Z; Brodszky V
BMC Public Health; 2024 May; 24(1):1320. PubMed ID: 38755599
[TBL] [Abstract][Full Text] [Related]
67. Parental opinions towards the "No Jab, No Pay" policy in Australia.
Trent MJ; Zhang EJ; Chughtai AA; MacIntyre CR
Vaccine; 2019 Aug; 37(36):5250-5256. PubMed ID: 31371225
[TBL] [Abstract][Full Text] [Related]
68. Preferences for Vaccination: Does Health Literacy Make a Difference?
Veldwijk J; van der Heide I; Rademakers J; Schuit AJ; de Wit GA; Uiters E; Lambooij MS
Med Decis Making; 2015 Nov; 35(8):948-58. PubMed ID: 26338176
[TBL] [Abstract][Full Text] [Related]
69. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
70. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
71. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
Dull PM; McIntosh ED
Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
[TBL] [Abstract][Full Text] [Related]
72. Quantifying population preferences around vaccination against severe but rare diseases: A conjoint analysis among French university students, 2016.
Seanehia J; Treibich C; Holmberg C; Müller-Nordhorn J; Casin V; Raude J; Mueller JE
Vaccine; 2017 May; 35(20):2676-2684. PubMed ID: 28408120
[TBL] [Abstract][Full Text] [Related]
73. Community acceptance and willingness-to-pay for a hypothetical Zika vaccine: A cross-sectional study in Indonesia.
Harapan H; Mudatsir M; Yufika A; Nawawi Y; Wahyuniati N; Anwar S; Yusri F; Haryanti N; Wijayanti NP; Rizal R; Fitriani D; Maulida NF; Syahriza M; Ikram I; Fandoko TP; Syahadah M; Asrizal FW; Aletta A; Jamil KF; Rajamoorthy Y; Hadisoemarto PF; Wagner AL; Groneberg DA; Kuch U; Sasmono RT; Müller R; Imrie A
Vaccine; 2019 Mar; 37(11):1398-1406. PubMed ID: 30739794
[TBL] [Abstract][Full Text] [Related]
74. Patient preferences for depression treatment programs and willingness to pay for treatment.
Morey E; Thacher JA; Craighead WE
J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
[TBL] [Abstract][Full Text] [Related]
75. Values for preventing influenza-related morbidity and vaccine adverse events in children.
Prosser LA; Bridges CB; Uyeki TM; Rêgo VH; Ray GT; Meltzer MI; Schwartz B; Thompson WW; Fukuda K; Lieu TA
Health Qual Life Outcomes; 2005 Mar; 3():18. PubMed ID: 15780143
[TBL] [Abstract][Full Text] [Related]
76. Preferences heterogeneity of health care utilization of community residents in China: a stated preference discrete choice experiment.
Jiang MZ; Fu Q; Xiong JY; Li XL; Jia EP; Peng YY; Shen X
BMC Health Serv Res; 2020 May; 20(1):430. PubMed ID: 32423447
[TBL] [Abstract][Full Text] [Related]
77. Meningococcal serogroup B vaccine: Knowledge and acceptability among parents in Italy.
Morrone T; Napolitano F; Albano L; Di Giuseppe G
Hum Vaccin Immunother; 2017 Aug; 13(8):1921-1927. PubMed ID: 28441109
[TBL] [Abstract][Full Text] [Related]
78. Mothers' preferences regarding new combination vaccines for their children in Japan, 2014.
Shono A; Kondo M
Hum Vaccin Immunother; 2017 Apr; 13(4):766-771. PubMed ID: 27905819
[TBL] [Abstract][Full Text] [Related]
79. Individual decisions to vaccinate one's child or oneself: A discrete choice experiment rejecting free-riding motives.
Verelst F; Willem L; Kessels R; Beutels P
Soc Sci Med; 2018 Jun; 207():106-116. PubMed ID: 29738898
[TBL] [Abstract][Full Text] [Related]
80. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
